Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011)
Male
Non-alcoholic Fatty Liver Disease/epidemiology
Sarcopenia
Sarcopenia/diagnosis
Sarcopenia/epidemiology
Non-alcoholic Fatty Liver Disease/etiology*
Non-alcoholic Fatty Liver Disease/diagnosis
610
Skeletal/metabolism
Sarcopaenia
Body Mass Index
03 medical and health sciences
Absorptiometry, Photon
Non-alcoholic Fatty Liver Disease
NAFLD
Republic of Korea
Insulin Resistance*
Prevalence
Skeletal/diagnostic imaging
Humans
Sarcopenia/complications*
Obesity
Absorptiometry
Muscle, Skeletal
Steatohepatitis
Retrospective Studies
2. Zero hunger
0303 health sciences
Obesity/diagnosis
Obesity/epidemiology
Middle Aged
Prognosis
Photon
Obesity/etiology*
3. Good health
Cross-Sectional Studies
Muscle
Female
Republic of Korea/epidemiology
Insulin Resistance
Follow-Up Studies
DOI:
10.1016/j.jhep.2015.02.051
Publication Date:
2015-03-12T17:36:57Z
AUTHORS (10)
ABSTRACT
Although sarcopaenia is associated with obesity-related comorbidities, its influence on non-alcoholic fatty liver disease (NAFLD) or steatohepatitis has not been fully determined. We aimed to investigate the direct relationship between sarcopaenia and NAFLD or steatohepatitis in the general population.We conducted a cross-sectional study using nationally representative samples of 15,132 subjects from the Korea National Health and Nutrition Examination Surveys 2008-2011. Subjects were defined as having NAFLD when they had higher scores from previously validated NAFLD prediction models such as the hepatic steatosis index, comprehensive NAFLD score and NAFLD liver fat score. BARD and FIB-4 scores were used to define advanced fibrosis in subjects with NAFLD. The skeletal muscle index (SMI) [SMI(%)=total appendicular skeletal muscle mass (kg)/weight (kg)×100] measured by dual-energy X-ray absorptiometry was used to diagnose sarcopaenia with cut points of 32.2% for men and 25.5% for women.SMI was inversely correlated with all NAFLD predicting scores (Ps<0.001). After stratification, sarcopaenic subjects had an increased risk of NAFLD regardless of obesity (odds ratios [ORs]=1.55 to 3.02, depending on models; all Ps<0.001) or metabolic syndrome (ORs=1.63 to 4.00, all Ps<0.001). Multiple logistic regression analysis also demonstrated this independent association between sarcopaenia and NAFLD after adjusting for confounding factors related to obesity or insulin resistance (ORs=1.18 to 1.22, all Ps<0.001). Furthermore, among the NAFLD population, subjects with lower SMIs were likely to have advanced fibrosis compared with non-sarcopaenic individuals (BARD and FIB-4: ORs=1.83 and 1.69, respectively; both Ps<0.001). Compared with non-exercised subjects, individuals who exercised regularly had a lower risk of NAFLD (p<0.001), particularly among obese people with well-preserved muscle mass.Sarcopaenia is associated with increased risks of NAFLD and advanced fibrosis, independent of obesity or metabolic control.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (46)
CITATIONS (279)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....